Science & Technology
Bispecific antibody targeting IgE-producing B cells for treating allergic diseases
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R41AI188995-01
Award Ceiling
$300K
Award Floor
$300K
Close Date
Jan 31, 2027
322 days leftTotal Funding
$300K
Expected Awards
1
Posted Date
Feb 1, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R41AI188995-01
Description
STTR Phase Phase I award: "Bispecific antibody targeting IgE-producing B cells for treating allergic diseases" awarded to CELLERGY PHARMA in WILMINGTON, Delaware. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $300,000. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.